I am surprised this hasn't be discussed more. _
Post# of 30025
Posted On: 11/11/2014 8:57:34 AM
I am surprised this hasn't be discussed more. _
"As a holding company, our strategy is to acquire undervalued assets, incubate them through critical de-risking milestones and thereafter seek to deliver value to our shareholders through strategic initiatives. We believe we are well positioned to deliver on that promise in the near-term with our diagnostic division, making for the first data point of success of the overall business model and positioning Amarantus to continue this model as we move forward. We believe wholeheartedly in LymPro, and want to ensure that it receives the necessary management focus and commercialization expertise for it to become the gold standard for Alzheimer’s diagnosis. We expect to have updates on this initiative in the near-term."
Sounds to me like they fully intend to shed the diagonstics division.
I wonder I they will sell off ELTO at some point as well.
"As a holding company, our strategy is to acquire undervalued assets, incubate them through critical de-risking milestones and thereafter seek to deliver value to our shareholders through strategic initiatives. We believe we are well positioned to deliver on that promise in the near-term with our diagnostic division, making for the first data point of success of the overall business model and positioning Amarantus to continue this model as we move forward. We believe wholeheartedly in LymPro, and want to ensure that it receives the necessary management focus and commercialization expertise for it to become the gold standard for Alzheimer’s diagnosis. We expect to have updates on this initiative in the near-term."
Sounds to me like they fully intend to shed the diagonstics division.
I wonder I they will sell off ELTO at some point as well.
(0)
(0)